The Mixed Phenotype of Asthma and COPD: the Overlap Syndrome
The Mixed Phenotype of Asthma and COPD: the Overlap Syndrome: A Comparison of Asthma Outcomes in Smoking vs Non-smoking Patients With an Incomplete Reversibility of Airway Obstruction (IRAO)
RATIONALE:
In asthmatic subjects, smoking can lead to several changes in disease characterictics. in smokers of more than 20 pack-years, chronic obstructive pulmonary disease (COPD) can be associated with asthma, also called asthma-COPD overlap syndrome (ACOS). Increasing data support the concept that ACOS is a clinical entity. However, this should be further studied in order to better target therapy.
AIM:
The objective of this study is to evaluate the comparative features of ACOS
METHODS:
This will be a descriptive study comparing the features of the ACOS with the features of asthmatic subjects with an incomplete reversibility of airway obstruction (IRAO).The study will be done over 1 or 2 visits (within a week interval), according to subjects' availability. The visit will include completion of different questionnaires (asthma control asthma quality of life, medical history, exacerbations, etc.), a thoracic examination, allergy skin-prick tests, spirometry and bronchodilator response, lung volumes and compliance measurements, exhaled nitric oxide measurement, blood sampling and a sputum induction.
調査の概要
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
-
Quebec、カナダ、G1V 4G5
- Institut Universitaire de cardiologie et de pneumologie de Quebec
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
ALL SUBJECTS
- Subjects aged 45 years and older.
- Free of any other respiratory condition, except for asthma and/or COPD, which may interfere with the tests.
- Asthma that requires a baseline treatment with inhaled corticosteroids and/or additional asthma medication.
- Free of respiratory infection in the 4 weeks preceding the study.
- No changes in the asthma and COPD-related medications in the 4 weeks preceding the study.
- If female, not pregnant (or lactating).
- Able to adhere to study procedures.
- Able and willing to provide written informed consent to participate in the study, in accordance with international conference on harmonization (ICH) good clinical practice (GCP) requirements.
ACOS SUBJECTS
1. Smokers or ex-smokers of at least 20 pack-years. 2. With an IRAO (see definitions section). IRAO SUBJECTS
- Long-life non-smokers or ex-smokers defined as someone who smoked less than 5 pack-years and who completely stopped smoking for at least 12 months before inclusion in the study.
- With an IRAO.
Exclusion Criteria:
ALL SUBJECTS
- With COPD without a past diagnosis of asthma.
- Unstable respiratory or non-respiratory condition.
- Any active chronic inflammatory disease.
- Any evidence of malignancy (active and/or treated) within the previous 5 years.
- Any significant concomitant illness or injury that would interfere with the subject's participation in the study.
- Any history of bronchial thermoplasty. IRAO SUBJECTS
- Use of any nicotine containing product within 1 year prior to study entry or a smoking history of > 5 pack-years.
研究計画
研究はどのように設計されていますか？
デザインの詳細
コホートと介入
グループ/コホート |
|---|
|
ACOS smoking history >20 pack-years
Subjects with asthma-COPD overlap syndrome
|
|
IRAO smoking history <5 pack-years
Subjects with an incomplete reversibility of airway obstruction
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Total asthma control questionnaire (ACQ) score
時間枠：Baseline
|
Measurement of asthma control using a 0-6 scale.
The questionnaire includes 6 questions.
Total score is the mean of the scores from all questions.
Total score ranges from 0 to 6.
A lower score is better.
|
Baseline
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Spirometry results
時間枠：Baseline
|
Forced expiratory volume in one second (FEV1), forced vital capacity (FVC), FEV1/FVC
|
Baseline
|
|
Sputum eosinophil percentage
時間枠：Baseline
|
Percentage of sputum eosinophils
|
Baseline
|
|
Concentration of Blood biomarkers
時間枠：Baseline
|
alpha 1 antitrypsine, C-reactive protein (CRP), fibrinogen
|
Baseline
|
|
Asthma quality of life questionnaire (AQLQ) score
時間枠：Baseline
|
Measurement of asthma quality of life using the Mini asthma quality of life questionnaire.
It is a 7-point scale questionnaire (where 1 is greatest impairment and 7 is least impairment) containing 15 uqestions divided into 4 domains : symptoms (5 items), activity limitation (4 items), emotional function (3 items), and exposure to environmental stimuli (3 items).
during the last 2 weeks.
The overall score is the mean of all the responses.
Each domain score is calculated from the mean of the items that relate to it.
|
Baseline
|
|
Number of patients with comorbidities
時間枠：Baseline
|
gastro-oesophageal reflux disease (GERD), obstructive sleep apnea (OSA), anxiety, depression
|
Baseline
|
|
Number of asthma exacerbations in the previous year
時間枠：Baseline
|
emergency room (ER) visits, hospitalizations, oral corticosteroids treatment, unscheduled medical visits
|
Baseline
|
|
Change from baseline total Asthma Control Questionnaire (ACQ) score at one-year follow-up
時間枠：Baseline to one-year follow-up
|
Measurement of asthma control using a 0-6 scale.
The questionnaire includes 6 questions.
Total score is the mean of the scores from all questions.
Total score ranges from 0 to 6.
A lower score is better.
|
Baseline to one-year follow-up
|
|
Change from baseline number of exacerbations at one-year follow-up
時間枠：Baseline to one-year follow-up
|
emergency room (ER) visits, hospitalizations, oral corticosteroids treatment, unscheduled medical visits
|
Baseline to one-year follow-up
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。